This family protocol summary provides a general overview of the Children's Oncology Group (COG) study ANHL12P1. It tells who is eligible and gives basic information about the study. More details about the study are in the consent form. You can get this from your oncologist.

ANHL12P1 is a Phase II clinical trial. A trial is another word for a study. This study (clinical trial) is a therapeutic clinical trial. That means it is done to learn about treatment - its safety and how well it works. The purpose of a Phase II trial is to learn if a new treatment works in treating a specific type of cancer and how it affects the body.

­­­­In a Phase II trial, patients with a specific type of cancer receive a new treatment using a dose that was found to be safe in a Phase I trial. Patients are checked for side effects of the treatment and to see whether the cancer shrinks or goes away.

In this study, each child is assigned to a study arm by a method called randomization. This is a process like flipping a coin that assures that each participant has a fair and equal chance of being assigned to any of the study arms. This makes sure the study arms can be compared fairly.

It is important to understand that participating in a clinical trial is entirely voluntary. The decision about whether or not to participate will not affect the care provided by the health care team in any way. You can find additional information about participation in clinical trials at Always discuss any questions that you may have with your health care team.

Study Number


Official Title

A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Study Opening Date

ANHL12P1 opened 11/08/2013. The study committee hopes to enroll 128 patients. It is expected that this study will remain open until each arm enrolls 70 patients, around spring 2017.

General Patient Eligibility

  • Age: younger than 22 years old
  • Diagnosis: Anaplastic Large Cell Lymphoma that has not been treated
    • Disease must be both CD30 positive and ALK positive (This means that the lymphoma cells have proteins called CD30 and ALK present on their surface)
  • Patients who have disease in the central nervous system (brain or spinal cord) are not eligible for this study

Please consult your doctor to determine whether your child may participate in this study.

General Background and Study Goal

Anaplastic Large Cell Lymphoma (ALCL) is a form of non-Hodgkin lymphoma and accounts for 10-15% of all childhood lymphomas. Many children with ALCL can be cured with current treatments, but the current treatment does not stop the cancer from coming back in some patients. Patients who have disease return or progress have a poor prognosis to achieve long lasting remission.

This study will add one of 2 new medications, Brentuximab Vedotin (BV) or Crizotinib (CZ), to standard chemotherapy. Brentuximab vedotin is a monoclonal antibody (brentuximab) linked to an anti-cancer drug (vedotin). The monoclonal antibody attaches to a receptor protein called CD30, which is present on the surface of anaplastic large cell lymphoma cells. After the brentuximab antibody attaches to the cells, the vedotin enters the cancer cells and kills them. BV has been studied in adults with Hodgkin Lymphoma and Non-Hodgkin lymphoma, with promising results. This study is the first trial specifically for children.

Crizotinib targets cancer cells that have proteins called ALK. Both of these drugs are used as "targeted" therapy. This means BV and Crizotinib will inhibit only the cells which have CD30 or ALK proteins on their surfaces.

Research on both of these drugs has shown impressive responses in patients whose disease has relapsed. It is hoped that adding one of these agents to standard chemotherapy will improve overall survival while minimizing side effects.

The goal of this study will be to determine what, if any, side effects a patient will experience when either BV or CZ is given along with standard chemotherapy. The study will also determine if survival can be improved adding either of these drugs to standard chemotherapy, compared to standard therapy alone, used in previous studies. A secondary goal will be to evaluate the amount of minimal residual disease (MRD) during therapy. MRD is a laboratory measurement that is able to detect very small amounts of lymphoma cells in the blood or bone marrow. Study doctors would like to determine if MRD testing can be used to identify patients who have a higher risk of recurrence.

Summary of the Treatment

This study will assign patients to different arms based on their size. Body surface area is calculated using height and weight, and the result is measured as "meter squared" (m2). The two arms on this study are:

  1. Patients with body surface area more than 0.9 m2
  2. Patients with body surface area less than 0.9 m2; these patients are currently not eligible for study due to brentuximab arm temporary closure.

Stratum a: Patients with a body surface area more than 0.9m2 will be randomized (assigned randomly by computer) to one of two arms: standard chemotherapy plus EITHER Brentuximab vedotin (Arm BV) OR Crizotinib (Arm CZ). The Brentuximab arm is closed to accrual in order to evaluate patient data.

Stratum b: Patients with a body surface area smaller than 0.9 m2 will be assigned to standard chemotherapy plus BV, because Crizotinib is only available in doses which are too high for patients with body surface area less than 0.9m2. This stratum is closed to accrual due to review of patient data.

Standard chemotherapy consists of a 5-day initial cycle of chemotherapy (called pro-phase), followed by 6 chemotherapy cycles that are each 21-days (three weeks) long.

  • Arm BV: Patients receive standard chemotherapy plus BV. BV will be given IV on the first day of each of the 6 cycles of chemotherapy
  • Arm CZ: Patients receive standard chemotherapy plus CZ. CZ will be given by mouth daily for 21 days during each of the 6 cycles of chemotherapy.

Special Considerations

  • Crizotinib is a pill, which cannot be opened or crushed. Crizotinib should be taken about the same time every day. It may be taken with food or on an empty stomach.
  • Blood will be obtained to evaluate minimal residual disease three times total during pro-phase and cycle 1. This can be done at the same time as other scheduled blood tests.
  • Certain medications cannot be taken while on this study. Please consult with your medical team.
  • To decrease the risk of blood clots, you/your teen, should avoid smoking or drugs that may increase risk of blood clots. Good hydration is also important in preventing blood clots. Consult your medical team for more information.

Risks and Side Effects

Chemotherapy can cause side effects during and after treatment. All patients will be closely monitored for possible side effects of the medicines. While monitoring for side effects, it has been discovered there is an increased risk of blood clots (also called "thromboembolitic events") occurring on the CZ arm. To prevent this from occurring, it is recommended that patients on this treatment arm, be put on blood thinners. Your physician will choose the best blood thinner for you. All risks and side effects will be explained by your treatment team during the consent process. They can answer any questions that you may have about giving permission for your child to be in the clinical trial or other aspects of care. Please refer to the consent form for a detailed explanation of the side effects associated with the treatment on this study.

Contact Information

Your child's oncologist and nurses are the best sources for further information.

Study Chair

Eric J. Lowe, M.D.

Children's Cancer and Blood Disorder Center


Initial development Name Date
Written by (protocol nurse) Debbie Woods CPNP March 19, 2015
Reviewed/approved by (PI) Eric J. Lowe, M.D October 14, 2015
Ongoing review
Reviewed and updated by Debbie Woods, CPNP February 17, 2017
January 31, 2018